Australian and New Zealand Intensive Care Society Clinical Trials Group
14
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.1%
1 terminated/withdrawn out of 14 trials
91.7%
+5.2% vs industry average
79%
11 trials in Phase 3/4
0%
0 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Role: collaborator
Fibrinogen Early In Severe Trauma StudY II
Role: collaborator
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial
Role: collaborator
Beta-Lactam InfusioN Group Study
Role: collaborator
Plasma-Lyte 148® versUs Saline Study
Role: collaborator
The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury
Role: collaborator
TEAM: A Trial of Early Activity and Mobility in ICU
Role: collaborator
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock
Role: collaborator
Erythropoietin in Traumatic Brain Injury (EPO-TBI)
Role: collaborator
Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial
Role: collaborator
Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes
Role: collaborator
Crystalloid Versus Hydroxyethyl Starch Trials
Role: collaborator
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Role: collaborator
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)
Role: collaborator
All 14 trials loaded